A randomized, double-blind placebo-controlled study of intranasal standardized cinnamon bark extract for seasonal allergic rhinitis

Steels, Eleanor; Steels, Emmanuelle; Deshpande, Pallavi; Thakurdesai, Prasad; Dighe, Satish N.; Collet, Trudi

doi:10.1016/j.ctim.2019.102198

Cited by 13 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mean posttreatment difference of –1.5 (95% CI, –2.4 to –0.5; P = .002) was demonstrated for the EpSS and –1.7 (95% CI, –2.1 to –1.2; P < .00001) for the PSQI. Twenty-two studies 26-47 informed on the sleep domain of the RQLQ, while 14 studies 26,29-31,33,35-38,41-43,45,48 reported the total RQLQ after treatment. A mean posttreatment difference of –1.1 (95% CI, –1.2 to –0.9; P < .00001) was calculated for the RQLQ sleep domain and –1.4 (95% CI, –1.6 to –1.1; P < .00001) for RQLQ total.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Treatment for Nasal Cavity Disorders on Sleep Quality: Systematic Review and Meta‐analysis

Fried

Yuen

Zhang

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To determine the impact of treatment for patients with nasal obstruction secondary to allergic rhinitis (AR) and nasal septal deviation (NSD) on sleep quality. Data Sources Primary studies were identified though PubMed, Scopus, Cochrane Library, and Web of Science. Review Methods A systematic review was performed by querying databases for articles published through August 2020. Studies were included that reported on objective sleep parameters (apnea-hypopnea index) and sinonasal and sleep-specific patient-reported outcome measures: Rhinoconjunctivitis Quality of Life Questionnaire, Nasal Obstruction Symptom Evaluation, Epworth Sleepiness Scale (EpSS), and Pittsburgh Sleep Quality Index (PSQI). Results The database search yielded 1414 unique articles, of which 28 AR and 7 NSD studies were utilized for meta-analysis. A total of 9037 patients (8515 with AR, 522 with NSD) were identified with a mean age of 35.0 years (35.3 for AR, 34.0 for NSD). Treatment for AR and NSD significantly improved subjective sleep quality. For AR, the EpSS mean difference was −1.5 (95% CI, –2.4 to –0.5; P = .002) and for the PSQI, –1.7 (95% CI, –2.1 to –1.2; P < .00001). For NSD, the EpSS mean difference was −3.2 (95% CI, –4.2 to –2.2; P < .00001) and for the PSQI, –3.4 (95% CI, –6.1 to –0.6; P = .02). Conclusion Subjective sleep quality significantly improved following treatment for AR and NSD. There were insufficient data to demonstrate that objective metrics of sleep quality similarly improved.

show abstract

Section: Resultsmentioning

confidence: 99%

“…00001) for the PSQI. Twenty‐two studies 26–47 informed on the sleep domain of the RQLQ, while 14 studies 26,29–31,33,35–38,41–43,45,48 reported the total RQLQ after treatment. A mean posttreatment difference of –1.1 (95% CI, –1.2 to –0.9; P <.…”

Section: Resultsmentioning

confidence: 99%

Impact of Treatment for Nasal Cavity Disorders on Sleep Quality: Systematic Review and Meta‐analysis

Fried

Yuen

Zhang

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“… the severity of the symptoms of SAR was decreased General activity impairment was reduced along with a corresponding improvement in quality of life and work productivity. [70] NM: not mentioned, LPS: Lipopolysaccharides, NF-kB: Nuclear factor- kappaB, TNF-a: tumor necrosis factor-a, IL: interleukin, PGE2: prostaglandin E2, HO: heme- oxygenase, NRF2: Nuclear factor erythroid 2-related factor 2, Th: T helper, IFN: Interferon, TTP: Tristetraprolin, VEGF: Vascular endothelial growth factor, ERK: extracellular signal-regulated kinases, NO: nitric oxide, IκBα: inhibitor of nuclear factor kappa B, MDA: Malondialdehyde, M-CSF: Macrophage-colony stimulating factor, HA: Haemagglutination, DTH: delayed-type hypersensitivity, PLCγ1: Phospholipase Cγ1, ConA: Concanavalin A, IgE: Immunoglobulin E, HUVECs: Human umbilical vein endothelial cells, ICAM-1: Intercellular Adhesion Molecule 1, β-HEX: Bet-hexosaminidase CAII: Carbonic anhydrase-II, BRCA1: breast cancer 1, PAI-1: Plasminogen activator inhibitor-1, SREBP-1: sterol regulatory element-binding protein 1, LXRs: liver X receptors, ACLY: ATP-citrate lyase, FAS: fatty acid synthase, PPARα: peroxisome proliferator-activated receptor α, DC: dendritic cells, OVA: ovalbumin, ADAMTS-5: A disintegrin and metalloproteinase with thrombospondin motifs 5, LTB4: Leukotriene B4, NFATc3: Nuclear Factor Of Activated T Cells 3, CHK: checkpoint kinase, MMPs: Matrix metalloproteinases, TLR: Toll-like receptor …”

Section: Potential Pharmacological Effects Of Cinnamon Against Covid-19mentioning

confidence: 99%

Cinnamon and its possible impact on COVID-19: The viewpoint of traditional and conventional medicine

Yakhchali

Taghipour

Ardakani

et al. 2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The COVID-19 global epidemic caused by coronavirus has affected the health and other aspects of life for more than one year. Despite the current pharmacotherapies, there is still no specific treatment, and studies are in progress to find a proper therapy with high efficacy and low side effects. In this way, Traditional Persian Medicine (TPM), due to its holistic view, can provide recommendations for the prevention and treatment of new diseases such as COVID-19. The muco-obstruction of the airway, which occurs in SARS-CoV-2, has similar features in TPM textbooks that can lead us to new treatment approaches. Based on TPM and pharmacological studies, Cinnamomum verum (Darchini)'s potential effective functions can contribute to SARS-CoV-2 infection treatment and has been known to be effective in corona disease in Public beliefs. From the viewpoint of TPM theories, Cinnamon can be effective in SARS-CoV-2 improvement and treatment through its anti-obstructive, diuretic, tonic and antidote effects. In addition, there is pharmacological evidence on anti-viral, anti-inflammatory, antioxidant, organ-o-protective and anti-depression effects of Cinnamon that are in line with the therapeutic functions mentioned in TPM. Overall, Cinnamon and its ingredients can be recommended for SARS-CoV2 management due to multi-targeting therapies. This review provides basic information for future studies on this drug's effectiveness in preventing and treating COVID-19 and similar diseases.

show abstract

“…The IND02 is reported to block the selectin binding and leukocytes adhesion with sialic acids to inhibit allergic inflammation 28 , inhibit the markers of allergic rhinitis (AR) such as histamine, Interleukin 4 (IL-4), and β-hexosaminidase in an Immunoglobulin E inhibition 29 , and mast cell stabilizing mechanisms 29 . Topical intranasal use of IND02-NS showed good efficacy against AR during animal studies 30 and patients 31,32 . However, the long-term safety of intranasal administration of IND02-NS is not yet reported.…”

Section: Introductionmentioning

confidence: 96%

Preclinical Safety Evaluation of Acute and Subacute Intranasal Administration of Polyphenols-based Cinnamon Bark Extract in Laboratory Rats

Thakurdesai¹,

Deshpande²

2021

Self Cite

View full text Add to dashboard Cite

were fed on pelleted feed (Altromin Spezialfutter GmbH and Co. KG, Germany, supplied by ATNT Laboratories, Mumbai, India) and provided with pure potable water in sterilized bottles with stainless steel sipper tubes. The rats were maintained at ambient temperature (19-25°C) and relative humidity (30-70%) with 12 h: 12 h of the dark: light cycle. The female rats were nulliparous and non-pregnant. The study

show abstract

A randomized, double-blind placebo-controlled study of intranasal standardized cinnamon bark extract for seasonal allergic rhinitis

Cited by 13 publications

References 32 publications

Impact of Treatment for Nasal Cavity Disorders on Sleep Quality: Systematic Review and Meta‐analysis

Impact of Treatment for Nasal Cavity Disorders on Sleep Quality: Systematic Review and Meta‐analysis

Cinnamon and its possible impact on COVID-19: The viewpoint of traditional and conventional medicine

Preclinical Safety Evaluation of Acute and Subacute Intranasal Administration of Polyphenols-based Cinnamon Bark Extract in Laboratory Rats

Contact Info

Product

Resources

About